Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non–small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials
ConclusionsThe available moderate evidences indicate that chemotherapy with CIK cells, especially autologous CIK cells, can significantly improve the tumor responses, 1- and 2-year overall and progression-free survival rates in patients with advanced NSCLC. This treatment does have a high risk of fever. The optimal use may be treatment with one or two cycles and in combination with vinorelbine and cisplatin, paclitaxel and cisplatin, or docetaxel and cisplatin.
Source: Cytotherapy - Category: Cytology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Clinical Trials | Cytology | Databases & Libraries | Docetaxel | Gastroenterology | Immunotherapy | International Medicine & Public Health | Liver | Lung Cancer | Non-Small Cell Lung Cancer | Science | Statistics | Study | Taxotere | Toxicology | Urology & Nephrology | WHO